Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Medifirst Solutions Announces a Business Update


Posted on: 16 Feb 18

FREEHOLD, NJ, Feb. 16, 2018 (GLOBE NEWSWIRE) --


MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce a business update. 

Medifirst recently announced that it was in negotiations to bring its FDA cleared Time Machine Laser to the China Market. With the recent addition of Life Science Quest, a medical device business development consulting firm, and the efforts and expertise of its founder Ruobing Xia, Medifirst will be meeting with a very prominent China-based medical organization to complete negotiations for a business venture that will involve exclusive rights to sell the Time Machine Laser for the entire country of China.  While no assurances can be made that the Company will complete an agreement when they meet in the upcoming weeks, the Company is pleased that after initial negotiations, the medical organization from China will be flying in for a scheduled a meeting in New York with intentions to set forth the terms of an agreement with Medifirst. Commented Medifirst’s President, Bruce Schoengood, “We are very excited to meet with a company that has close business relationships with many of China’s leading hospitals and medical organizations. Both parties believe that there is a huge market with great potential and a great need for all-natural pain treatments such as the Time Machine Laser for use in the China medical community.” 

The Company recently presented its Infrared Laser at the Greater New York Dental Meeting held in the Jacob Javits Center. The Time Machine Laser has shown effective and immediate results for patients suffering from pain related to their temporomandibular joint (TMJ). We believe TMJ treatment provides Medifirst with a very strong, untapped, niche application for dental practitioners. Medical professionals are looking for safe alternative means of treating TMD/TMJ pain without harmful drugs or surgery. Medifirst and the Time Machine Laser have developed pain management programs for people suffering from TMJ. 

TMD/TMJ dysfunction patients have been the scourge and struggle of most dentists. Due to their pain and trismus (lock jaw), the patients cannot cooperate while dentists take their dental impressions. This prevents an accurate impression of the needed inter-cuspal relationships to fabricate functional bite splints and restorations. We believe that the Time Machine Laser provides a solution. Our FDA cleared TTML Infrared Laser is able to reduce TMD pain rapidly, and without drugs. This is a major benefit for the doctors and their patients. Most often, after just one session, patients usually have as much as a 50% decrease in pain, and as it breaks the muscle spasm, the trismus is often decreased up to one cm or more. The patient is now relaxed and pain free and the dentist can proceed to making the most successful bite splits, appliances and dental reconstructions possible. We believe TMJ treatment provides Medifirst with a very strong, untapped, niche application for dental practitioners. 

Medifirst is pleased to announce that it currently has five dental centers using the Time Machine Laser for TMJ pain and disorders. The company believes that these centers will serve as a model for growth and further applications of the lasers for the entire dental community. The Infrared Laser has recently been incorporated into the treatment protocols for a new major cutting-edge Sleep Apnea Program designed to treat patients in a less intrusive and more comfortably manner than the airway pressure machines with a variety of breathing masks which are the most widely used treatment for moderate and severe Sleep Apnea.  Congress has been proposing legislation for city and states to test and treat transit workers, train engineers and truck drivers for Sleep Apnea as recent studies show that many workers suffer from this sleep disorder which can be the cause of accidents. Medifirst believes its Time Machine Laser will play a vital role in the treatment of Sleep Apnea. Medifirst is also considering a rental model which will include a Time Machine Laser marketing program directed to the dentists and specialists who use the laser. With this payment model, Medifirst will continue to have recurring monthly revenue and offer doctors the added value of driving new patients and business to their practice.

Medifirst anticipates further announcements in the upcoming days and weeks on additional company developments.  

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions.  The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

Forward-Looking Statements:  

The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

CONTACT: Contact:    Investor Relations Phone:  (732) 786-8044 Email:   admin@medifirstsolutions.com Website:  www.medifirstsolutions.comGlobeNewswire
globenewswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.